Cash figures as of 2026-04-30. Database snapshot: 2026-09-21.
Price history
Loading RFL daily closes…
Loading price history…
Pipeline assets
Trappsol Cyclo
Phase 3 · Active
Partnerships Massachusetts Institute of Technology: exclusive worldwide royalty-bearing patent license (Apr 16, 2026) for products containing hydroxypropyl-beta-cyclodextrin as the active ingredient in the field of Alzheimer’s disease; milestones include dosing the first patient in a U.S. Phase II trial by Mar 31, 2027
Indications
Niemann-Pick disease type C1 (NPC1)(Phase 3)
Alzheimer’s disease (APOE4 carriers)(Stage not disclosed)
Catalysts
— second half of calendar 2026
— second half of calendar 2026
— by Mar 31, 2027
Status note Lead candidate; active ingredient is hydroxypropyl-beta-cyclodextrin. Pivotal Phase 3 TransportNPC study in NPC1: last patient completed the final 96-week visit (announced Jun 2026); pre-NDA meeting with FDA completed.
Per-asset detail extracted from the 10-Q filed 2026-06-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.